U.S. Markets closed

Innoviva, Inc. (INVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.07+0.31 (+2.64%)
At close: 04:00PM EDT
11.51 -0.56 (-4.64%)
After hours: 06:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close11.76
Bid12.00 x 1400
Ask12.25 x 1000
Day's Range11.85 - 12.09
52 Week Range11.57 - 20.71
Avg. Volume726,952
Market Cap838.771M
Beta (5Y Monthly)0.50
PE Ratio (TTM)5.32
EPS (TTM)2.27
Earnings DateOct 25, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 08, 2015
1y Target Est18.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for INVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Innoviva, Inc.
    INVA: What does Argus have to say about INVA?INNOVIVA INC has an Investment Rating of HOLD; a target price of $13.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • Benzinga

    Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings

    Theravance Biopharma Inc (NASDAQ: TBPH) is buying back over 9.6 million shares from GSK plc (NYSE: GSK) for roughly $94 million, according to an SEC filing. In addition, Theravance plans to buy back $95 million from its existing investors "in the near term" and another $60 million in its shares on the open market. In a press release, Theravance says it hopes to complete that part of its plan by the end of 2023. Related content: Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patien

  • Business Wire

    Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

    BURLINGAME, Calif., September 08, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.

  • Simply Wall St.

    Investing in Innoviva (NASDAQ:INVA) three years ago would have delivered you a 16% gain

    It hasn't been the best quarter for Innoviva, Inc. ( NASDAQ:INVA ) shareholders, since the share price has fallen 12...